TP53 and neoplasm: Specific T cell-mediated immunotherapy requires the identification of tumor-specific antigens carrying T cell epitopes presented in the context of MHC class I and/or MHC class II molecules (reviewed by[19,20,60,61]) An attractive tumor specific antigen in ovarian cancer is the frequently overexpressed and mutated p53 protein.